{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:33:32Z","timestamp":1789065212222,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s13181-022-00925-z","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T19:02:52Z","timestamp":1672167772000},"page":"219-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diphenhydramine-Induced Antimuscarinic Delirium Treated with Physostigmine and Transdermal Rivastigmine"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6927-4427","authenticated-orcid":false,"given":"James D.","family":"Whitledge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. James","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Bakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leora","family":"Boussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"issue":"2","key":"925_CR1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13181-022-00888-1","volume":"18","author":"P Soto","year":"2022","unstructured":"Soto P, Johnson-Arbor K, Fox ER, Mazer-Amirshahi M. ACMT Annual Scientific Meeting Abstracts \u2013 Virtual. Abstract 024: Drug shortages impacting agents for anticholinergic delirium. J Med Toxicol. 2022;18(2):75\u2013125.","journal-title":"J Med Toxicol"},{"key":"925_CR2","unstructured":"Cozanitis DA. Galanthamine hydrobromide, a longer-acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine). Anaesthesist. 1977;26(12):649\u201350."},{"issue":"5","key":"925_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/15563650.2020.1818768","volume":"59","author":"MW Van Kernebeek","year":"2021","unstructured":"Van Kernebeek MW, Ghesquiere M, Vanderbruggen N, Verhoeven E, Hubloue I, Crunelle CL. Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication. Clin Toxicol. 2021;59(5):447\u20138.","journal-title":"Clin Toxicol"},{"issue":"5","key":"925_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0278-5846(03)00119-2","volume":"27","author":"M Ays\u0131n Noyan","year":"2003","unstructured":"Ays\u0131n Noyan M, Elbi H, Aksu H. Donepezil for anticholinergic drug intoxication: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):885\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"925_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.euroneuro.2017.05.006","volume":"27","author":"SI Sandia","year":"2017","unstructured":"Sandia SI, Ram\u00edrez VJ, Pi\u00f1ero AJ, Baptista TT. Treating \u2018Devil\u05f3s Breath\u05f3H intoxication: use of rivastigmine in six patients with toxic psychoses due to non pharmaceutical scopolamine. Eur Neuropsychopharmacol. 2017;27(8):833\u20134.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"925_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/15563650.2020.1854281","volume":"59","author":"GS Wang","year":"2021","unstructured":"Wang GS, Baker K, Ng P, Janis GC, Leonard J, Mistry RD, et al. A randomized trial comparing physostigmine vs. lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol. 2021;59(8):698\u2013704.","journal-title":"Clin Toxicol"},{"issue":"4","key":"925_CR7","first-page":"329","volume":"20","author":"SW Gee","year":"2015","unstructured":"Gee SW, Lin A, Tobias JD. Dexmedetomidine infusion to control agitation due to anticholinergic toxidromes in adolescents, a case series. J Pediatr Pharmacol Ther. 2015;20(4):329\u201334.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"925_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bcp.12839","volume":"81","author":"AH Dawson","year":"2016","unstructured":"Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice: anticholinergic delirium. Br J Clin Pharmacol. 2016;81(3):516\u201324.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"925_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/15563650.2020.1869757","volume":"59","author":"AR Hughes","year":"2021","unstructured":"Hughes AR, Moore KK, Mah ND, Birmingham AR, Clark RK, Thompson JA, et al. Letter in response to Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication. Clin Toxicol. 2021;59(9):855\u20136.","journal-title":"Clin Toxicol"},{"issue":"3","key":"925_CR10","doi-asserted-by":"publisher","first-page":"e226836","DOI":"10.1136\/bcr-2018-226836","volume":"12","author":"J Ahmad","year":"2019","unstructured":"Ahmad J, Hasan MJ, Anam AM, Barua DK. Donepezil: an unusual therapy for acute diphenhydramine overdose. BMJ Case Rep. 2019;12(3):e226836.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"925_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jat\/bkr015","volume":"36","author":"WC Rodrigues","year":"2012","unstructured":"Rodrigues WC, Castro C, Catbagan P, Moore C, Wang G. Immunoassay screening of Diphenhydramine (Benadryl(R)) in urine and blood using a newly developed assay. J Anal Toxicol. 2012;36(2):123\u20139.","journal-title":"J Anal Toxicol"},{"issue":"1\u20132","key":"925_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/15563658708992613","volume":"25","author":"C K\u00f6ppel","year":"1987","unstructured":"K\u00f6ppel C, Ibe K, Tenczer J. Clinical symptomatology of diphenhydramine overdose: an evaluation of 136 cases in 1982 to 1985. J Toxicol Clin Toxicol. 1987;25(1\u20132):53\u201370.","journal-title":"J Toxicol Clin Toxicol"},{"key":"925_CR13","unstructured":"Exelon patch (rivastigmine) label [Internet]. Novartis Pharmaceuticals Corporation; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022083lbl.pdf. Accessed 29 Aug 2022."},{"issue":"4","key":"925_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0091270006297748","volume":"47","author":"G Lef\u00e8vre","year":"2007","unstructured":"Lef\u00e8vre G, S\u0119dek G, Huang HLA, Saltzman M, Rosenberg M, Kiese B, et al. Pharmacokinetics of a Rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol. 2007;47(4):471\u20138.","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-022-00925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-022-00925-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-022-00925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T13:36:10Z","timestamp":1680010570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-022-00925-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s13181-022-00925-z","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"22 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}